Mont Vert Group Signs $500 Million Deal to Build Medical University and Hospital in Kazakhstan
Pune (Maharashtra) [India], June 14: Pune-based leading real estate firm Mont Vert Group has signed a $500 million (approx. ₹4,300 crore) agreement with Kazakhstan's Big B Corporation to develop a medical university and a multi-specialty hospital in Kazakhstan.
The announcement was made during the 30th anniversary celebration of SRAM & MRAM Group, held at Raven's Ait Private Island in London. The event was graced by notable dignitaries including Mr. Jayantilal Kaneria, Chairman, Mont Vert Group, Mr. Neeraj Kaneria, Managing Director, Mont Vert Group, Mr. Ajay Bhandari, Director, Big B Corporation (Kazakhstan), Mr. Mahendra Joshi, Director, SRAM & MRAM Group, Mr. Nitin Gupta, and Dr. Swapnil Kamble, all Directors of SRAM & MRAM Group.
As per a press release by UK-based SRAM & MRAM Group, Mont Vert Group has been entrusted with the construction and development of this project. This private healthcare initiative is being undertaken jointly by SRAM & MRAM Group, Big B Corporation, and KAZIND Medical Group of Kazakhstan.
The deal was made possible due to the efforts of Mr. Ajay Bhandari and Mr. Mahendra Joshi, Directors of Big B Corporation and SRAM & MRAM Group respectively.
Last October, the Kazakh government approved 243 hectares of land in Astana and 100 hectares in Almaty for the project. The campus will house a medical college accommodating 10,000 students and a multi-specialty hospital with 1,000 beds.
Mont Vert Group, a trusted name in Pune's real estate landscape, has successfully delivered over 6.8 million square feet of residential and commercial projects. Chairman Mr. Jayantilal Kaneria and Managing Director Mr. Neeraj Kaneria bring over 30 years of experience to the industry.
Mr. Sailesh Lachu Hiranandani, Chairman of SRAM & MRAM Group, said, "Mont Vert Group represents the pinnacle of excellence in Indian real estate. Their experience and quality commitment make them the ideal partner for this international healthcare venture."
(ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 minutes ago
- Time of India
Trump calls India's economy 'dead' – but that makes no sense
Recently, Donald Trump, the former U.S. President, made fun of India's economy by calling it 'dead.' But that's a strange and silly thing to say. Think about it: An economy is alive as long as people are buying, selling, and trading things — even if it's just one person giving a teabag to a friend in exchange for some biscuits. That's still trade! India has over 1.4 billion people, which means there are tons of trades and businesses happening every second. So how can it be 'dead'? Also, if India's economy was really dead, why is Trump so eager to sell things like soybeans, corn, and butter to India? You don't trade with something that isn't working. He even spent four months trying to make a trade deal — and only gave up when he got frustrated and added extra taxes (called tariffs) on Indian goods. India's economy is actually growing faster than any other big country's right now. That's not what a dead economy looks like. Even countries that aren't growing fast — like Japan — are still very much alive and running. Trump has said strange things before. Once, he told a man his father would be proud 'looking down on him,' thinking the father had passed away. But the man said his dad was still alive. Trump just replied, 'Then he's even more proud!' So when Trump says 'dead,' it might not mean what you think — or it might not mean anything at all. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Mint
5 minutes ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
Time of India
19 minutes ago
- Time of India
Dieticians back traditional Indian foods for lactating mothers, but with a scientific twist
Nagpur: Clinical dieticians and doctors trained in modern medicine are now advocating the use of traditional Indian postnatal foods like 'gond laddoos', and dry fruits to support lactation, but with necessary modifications rooted in science. Tired of too many ads? go ad free now Speaking during World Breastfeeding Week (August 1–7), the Indian Dietetic Association (IDA), Nagpur Chapter and NetProFan, Nagpur Chapter, jointly emphasised that traditional foods, long trusted by Indian households, can still be effective in boosting milk production if consumed in a modern, balanced form. "Traditional Indian postnatal diets were rich in ghee and sugar, aimed at restoring strength and enhancing lactation. But given current issues like postpartum weight gain, gestational diabetes, and anaemia, we need to update these recipes for today's mothers," said Dr Renuka Mainde, convener of NetProFan, Nagpur Chapter. "Instead of consuming heavy ghee-laden laddoos, we now recommend powdered versions of the same ingredients — like gond, nuts, and seeds — with milk or porridge. This maintains nutritional value without adding health risks," she said. Dr Kavita Bakshi, convener of IDA, Nagpur Chapter, added, "Some mothers struggle to produce enough milk due to poor nutrition. Foods like oats, almonds, flaxseeds, fennel, papaya, and leafy greens — rich in B-vitamins, iron, and healthy fats — are natural galactagogues. But all of this should be part of a balanced diet, and not a replacement for proper medical advice." Dr Kavita Gupta, secretary of IDA, Nagpur Chapter, explained how breastfeeding benefits extend to both mother and child. Tired of too many ads? go ad free now "It improves glucose tolerance, reduces risk of diabetes and breast cancer, and lowers high blood pressure in women with hyperglycemia in pregnancy. The longer the duration, the better the benefit," Gupta said. She also cautioned lactating women with diabetes to consult doctors before taking any medicines. "Insulin remains the safest, but Metformin and Glipizide are also considered safe in breastfeeding as they do not significantly pass into breast milk," Gupta said. Chanchal Sahani, joint secretary, IDA, Nagpur, pointed out the added value of breast milk in building a baby's immunity, brain development, and emotional bonding while being eco-friendly and cost-effective. "Breastfeeding is a skill. Proper latch and positioning not only help the baby feed better but also prevent problems like nipple pain, engorgement, and low supply," said Shalini Kotamkar, Life Member of IDA. BOX DIETICIANS SUGGEST * Gond laddoos should be consumed in powdered form with milk or porridge instead of heavy ghee-rich pieces * Use unsaturated fats from nuts and seeds instead of excess ghee * Include iron-rich leafy vegetables, pulses, and whole grains to combat anaemia * Avoid fried snacks with trans fats that delay postnatal recovery * Balance sugar intake in traditional sweets to prevent postpartum weight gain and blood sugar spikes
